CymaBay Therapeutics - CBAY Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $11.25
Forecasted Upside: 44.23%
Number of Analysts: 3
Breakdown:
0 Sell Ratings
0 Hold Ratings
2 Buy Ratings
1 Strong Buy Ratings

^$7.80 As of 01/27/2023 01:00 AM ET

▼ -0.26 (-3.23%)

1 month | 3 months | 12 months

Get New CymaBay Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for CBAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CBAY

^$11.25

▲ +44.23% Upside Potential

This price target is based on 3 analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. The average price target is $11.25, with a high forecast of $17.00 and a low forecast of $8.00. The average price target represents a 44.23% upside from the last price of $7.80.

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in CymaBay Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

1 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/6/2021

1 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/4/2021

1 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/2/2022

1 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/3/2022

1 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/1/2022

1 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/30/2022

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/29/2022

1 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/28/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
1/17/2023	Raymond James	Boost Target	Strong-Buy	$14.00 ➝ $17.00	Low
11/17/2022	Oppenheimer	Lower Target		$10.00	Low
5/18/2022	B. Riley	Lower Target	Buy	$10.00 ➝ $8.00	High
5/16/2022	Oppenheimer	Lower Target	NA	$12.00	N/A
5/16/2022	HC Wainwright	Lower Target	NA	$12.00 ➝ $10.00	Medium
4/1/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		N/A
11/11/2021	Raymond James	Boost Target	Strong-Buy	$12.00 ➝ $14.00	High
8/18/2021	B. Riley	Lower Target	Buy	$13.00 ➝ $10.00	Medium
8/15/2021	SVB Leerink	Reiterated Rating	Buy	$10.00	High
8/3/2021	HC Wainwright	Lower Target	Buy	$13.00 ➝ $12.00	Low
6/21/2021	Jonestrading	Reiterated Rating	Buy	$8.00	Medium
6/14/2021	Jonestrading	Initiated Coverage	Buy	$8.00	Medium
5/18/2021	SVB Leerink	Reiterated Rating	Buy	$10.00	Medium
3/31/2021	Cantor Fitzgerald	Lower Target	Hold ➝ Overweight	$20.00 ➝ $7.00	Medium
3/9/2021	Piper Sandler	Reiterated Rating	Buy	$12.00	Low
11/30/2020	Smith Barney Citigroup	Boost Target		$9.00 ➝ $10.00	Low
11/6/2020	Raymond James	Boost Target	Strong-Buy	$11.00 ➝ $12.00	High
11/6/2020	SVB Leerink	Boost Target	Outperform	$8.00 ➝ $10.00	High
10/9/2020	Cantor Fitzgerald	Reiterated Rating	Overweight		Medium
9/29/2020	Lifesci Capital	Reiterated Rating	Outperform		Medium
9/10/2020	Oppenheimer	Reiterated Rating	Buy	$14.00	Medium
9/9/2020	B. Riley	Boost Target		$9.00 ➝ $13.00	High
8/25/2020	Citigroup	Boost Target	Buy	$7.00 ➝ $9.00	Medium
8/12/2020	B. Riley	Reiterated Rating	Buy	$9.00	Low
8/11/2020	Raymond James	Boost Target	Strong-Buy	$10.00 ➝ $11.00	High
8/4/2020	Cantor Fitzgerald	Boost Target	Overweight	$15.00 ➝ $20.00	High
8/4/2020	HC Wainwright	Boost Target	Buy	$9.00 ➝ $13.00	High
8/4/2020	B. Riley	Reiterated Rating	Buy	$9.00	High
8/3/2020	Oppenheimer	Initiated Coverage	Buy	$12.00	High
8/3/2020	Stifel Nicolaus	Boost Target	Hold ➝ Buy	$8.00 ➝ $13.00	High
7/30/2020	Piper Sandler	Initiated Coverage	Overweight	$12.00	High
7/23/2020	Oppenheimer	Boost Target	Hold ➝ Outperform	$6.00 ➝ $10.00	High
7/23/2020	Raymond James	Upgrade	Outperform ➝ Strong-Buy		High
6/22/2020	B. Riley	Reiterated Rating	Buy	$6.00	High
5/26/2020	HC Wainwright	Upgrade	Neutral ➝ Buy	$9.00	Medium
5/15/2020	Citigroup	Boost Target	Buy	$1.60 ➝ $7.00	Low
5/12/2020	B. Riley	Upgrade	Neutral ➝ Buy	$1.50 ➝ $6.00	Medium
5/12/2020	Roth Capital	Upgrade	Neutral ➝ Buy	$15.00	High
5/12/2020	Cantor Fitzgerald	Boost Target	Hold ➝ Overweight	$5.00 ➝ $15.00	High
5/12/2020	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$2.50 ➝ $6.00	High
5/12/2020	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$4.00 ➝ $8.00	High
5/12/2020	Raymond James	Upgrade	Market Perform ➝ Outperform	$7.00	High
5/12/2020	Evercore ISI	Upgrade	In-Line ➝ Outperform	$15.00	High
3/20/2020	Citigroup	Lower Target	Buy	$2.00 ➝ $1.60	Low
3/18/2020	B. Riley	Lower Target	Neutral	$2.00 ➝ $1.50	High
3/13/2020	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$2.00 ➝ $5.00	High
3/12/2020	Oppenheimer	Upgrade	Market Perform ➝ Buy	$4.00	High
1/30/2020	HC Wainwright	Reiterated Rating	Hold		High
1/2/2020	SVB Leerink	Reiterated Rating	Market Perform		Medium
12/20/2019	HC Wainwright	Reiterated Rating	Neutral		Low
11/27/2019	B. Riley	Reiterated Rating	Hold	$2.00	Low
11/26/2019	Roth Capital	Downgrade	Buy ➝ Neutral	$22.00 ➝ $2.00	High
11/26/2019	HC Wainwright	Downgrade	Buy ➝ Neutral	$16.00 ➝ $2.00	High
11/26/2019	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral	$20.00 ➝ $2.00	High
11/26/2019	Raymond James	Downgrade	Strong-Buy ➝ Market Perform		High
11/25/2019	Oppenheimer	Downgrade	Outperform ➝ Hold		N/A
11/25/2019	SunTrust Banks	Downgrade	Buy ➝ Hold		N/A
11/25/2019	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$4.00	N/A
11/24/2019	Evercore ISI	Reiterated Rating	Buy	$12.00	High
11/6/2019	HC Wainwright	Reiterated Rating	Buy		Medium
9/18/2019	Cantor Fitzgerald	Set Target	Buy	$20.00	Low
8/14/2019	Evercore ISI	Reiterated Rating	Buy	$15.00	Low
6/24/2019	Stifel Nicolaus	Initiated Coverage	Buy ➝ Buy	$14.00	Low
6/17/2019	B. Riley	Set Target	Hold	$7.00	Low
6/13/2019	Citigroup	Lower Target	Buy	$21.00 ➝ $12.00	High
6/12/2019	HC Wainwright	Reiterated Rating	Buy	$24.00 ➝ $12.00	Low
6/11/2019	B. Riley	Set Target	Hold	$11.00	High
6/11/2019	Oppenheimer	Set Target	Buy	$12.00	High
6/11/2019	Piper Jaffray Companies	Lower Target	Overweight ➝ Buy	$30.00 ➝ $8.00	High
5/14/2019	Citigroup	Initiated Coverage	Buy ➝ Buy	$21.00 ➝ $21.00	High
4/23/2019	Raymond James	Set Target	Buy	$18.00	Low
4/14/2019	Oppenheimer	Set Target	Buy	$18.00	Medium
4/14/2019	Cantor Fitzgerald	Set Target	Buy	$20.00	Medium
3/1/2019	Piper Jaffray Companies	Set Target	Buy	$30.00	High
2/28/2019	Cantor Fitzgerald	Set Target	Buy	$20.00	High
2/22/2019	SVB Leerink	Initiated Coverage	Outperform	$22.00	High
2/21/2019	SVB Leerink	Reiterated Rating	Outperform		Medium
2/20/2019	Piper Jaffray Companies	Set Target	Buy	$30.00	Low
2/19/2019	Roth Capital	Reiterated Rating	Buy		Low
2/15/2019	Oppenheimer	Set Target	Buy	$18.00	High
2/5/2019	B. Riley	Initiated Coverage	Hold	$9.00 ➝ $9.00	Medium
2/1/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$20.00	High
12/9/2018	Oppenheimer	Set Target	Buy	$18.00	Medium
11/23/2018	Cantor Fitzgerald	Reiterated Rating	Overweight		High
11/19/2018	HC Wainwright	Reiterated Rating	Buy		High
11/13/2018	Oppenheimer	Set Target	Buy	$18.00	Low
11/7/2018	Oppenheimer	Set Target	Buy	$18.00	Low
11/7/2018	Cantor Fitzgerald	Set Target	Buy	$17.00	High
10/5/2018	Oppenheimer	Set Target	Buy	$20.00	Low
8/10/2018	Piper Jaffray Companies	Boost Target	Overweight	$30.00	Low
8/9/2018	Oppenheimer	Set Target	Buy	$20.00	High
8/9/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$16.00	High
6/28/2018	Raymond James	Initiated Coverage	Outperform	$20.00	Medium
6/6/2018	HC Wainwright	Reiterated Rating	Buy	$21.00 ➝ $23.00	Medium
5/9/2018	Oppenheimer	Set Target	Buy	$20.00	High
4/17/2018	Oppenheimer	Set Target	Buy	$20.00	Low
4/13/2018	HC Wainwright	Boost Target	Buy	$21.00	Low
4/11/2018	Oppenheimer	Set Target	Buy	$18.00	Medium
4/11/2018	SVB Leerink	Boost Target	Outperform	$16.00 ➝ $20.00	High
3/28/2018	HC Wainwright	Initiated Coverage	Buy	$18.00	Medium
3/21/2018	Oppenheimer	Reiterated Rating	Buy		Medium
3/16/2018	SunTrust Banks	Reiterated Rating	Buy	$19.00	High
3/16/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$16.00	High
3/16/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$16.00	Low
3/12/2018	Oppenheimer	Set Target	Buy	$18.00	High
2/13/2018	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform		High

(Data available from 1/29/2018 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

4 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

7/3/2022

4 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

8/2/2022

5 very positive mentions
7 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

9/1/2022

2 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/1/2022

5 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/31/2022

4 very positive mentions
6 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/30/2022

1 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/30/2022

4 very positive mentions
5 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/29/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

americanbankingnews.com
1/24/2023
Brokerages Set CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Target Price at $11.25
americanbankingnews.com
1/19/2023
Cantor Fitzgerald Analysts Decrease Earnings Estimates for CymaBay Therapeutics, Inc. (NASDAQ:CBAY)
americanbankingnews.com
1/19/2023
CymaBay Therapeutics (NASDAQ:CBAY) PT Raised to $17.00
americanbankingnews.com
1/18/2023
CymaBay Therapeutics (NASDAQ:CBAY) Hits New 1-Year High After Analyst Upgrade
markets.businessinsider.com
1/9/2023
CymaBay, Kaken To Develop And Commercialize Seladelpar In Japan For Primary Biliary Cholangitis

Very Positive

americanbankingnews.com
1/24/2023
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Short Interest Update
marketbeat.com
1/23/2023
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Short Interest Up 7.8% in December
finance.yahoo.com
1/17/2023
Here's What Could Help CymaBay Therapeutics Inc. (CBAY) Maintain Its Recent Price Strength
finance.yahoo.com
1/8/2023
CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Today's Range

Now: $7.80

$7.77

$8.35

50 Day Range

MA: $5.23

$3.27

$8.06

52 Week Range

Now: $7.80

$1.67

$8.40

Volume

1,325,582 shs

Average Volume

1,621,746 shs

Market Capitalization

$660.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.19

Frequently Asked Questions

What sell-side analysts currently cover shares of CymaBay Therapeutics?: The following Wall Street sell-side analysts have issued research reports on CymaBay Therapeutics in the last twelve months: B. Riley, Cantor Fitzgerald, HC Wainwright, Oppenheimer Holdings Inc., Raymond James, and StockNews.com.
View the latest analyst ratings for CBAY.
What is the current price target for CymaBay Therapeutics?: 4 Wall Street analysts have set twelve-month price targets for CymaBay Therapeutics in the last year. Their average twelve-month price target is $11.25, suggesting a possible upside of 44.2%. Raymond James has the highest price target set, predicting CBAY will reach $17.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $8.00 for CymaBay Therapeutics in the next year.
View the latest price targets for CBAY.
What is the current consensus analyst rating for CymaBay Therapeutics?: CymaBay Therapeutics currently has 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CBAY will outperform the market and that investors should add to their positions of CymaBay Therapeutics.
View the latest ratings for CBAY.
What other companies compete with CymaBay Therapeutics?: Other companies that are similar to CymaBay Therapeutics include Mersana Therapeutics, Viking Therapeutics, Amneal Pharmaceuticals, Fulcrum Therapeutics and MorphoSys. Learn More about companies similar to CymaBay Therapeutics.
How do I contact CymaBay Therapeutics' investor relations team?: CymaBay Therapeutics' physical mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company's listed phone number is (510) 293-8800 and its investor relations email address is [email protected] The official website for CymaBay Therapeutics is www.cymabay.com. Learn More about contacing CymaBay Therapeutics investor relations.

CymaBay Therapeutics - CBAY Stock Price Target and Predictions

Analyst Price Target for CBAY

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.78 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of CymaBay Therapeutics?

What is the current price target for CymaBay Therapeutics?

What is the current consensus analyst rating for CymaBay Therapeutics?

What other companies compete with CymaBay Therapeutics?

How do I contact CymaBay Therapeutics' investor relations team?